Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02559245
Other study ID # makan.pourmasoumi@gmail.com
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2015
Est. completion date January 2016

Study information

Verified date May 2018
Source Isfahan University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates effect of Ficus carica and Descurainia Sophia on irritable bowel syndrome predominant constipation. one-third of patients will receive Ficus carica, another one-third will receive Descurainia Sophia and remained patients only will follow their regular diet for 4 months.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- patients with irritable bowel syndrome predominant constipation

Exclusion Criteria:

- Subjects with significant cardiovascular, renal, hepatic, pulmonary, endocrine, metabolic, hematologic disorders,

- structural abnormalities of the gastrointestinal tract or

- diseases /conditions that affected bowel transition,

- surgery,

- any prokinetic or laxative drug used during the past month,

- any medication that may affect gastrointestinal motility,

- other therapeutic dietary advice for IBS,

- used Fig or Flixweed during the last month,

- diarrhea,

- pregnancy or

- breast-feeding

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Descurainia Sophia

Ficus carica


Locations

Country Name City State
Iran, Islamic Republic of Gastrointestinal Research Center Isfahan

Sponsors (1)

Lead Sponsor Collaborator
Isfahan University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary irritable bowel syndrome constipation predominant symptom IBS severity score system questionnaires will use for evaluation of IBS-C symptoms at the pre and post-intervention. This tool is validated for use in IBS patients that assess 5 clinically relevant items during past 10-days and including severity of abdominal pain, frequency of abdominal pain, severity of abdominal distention, dissatisfaction with bowel movement and interference of IBS with life in general. Each items was scored with a 100 mm visual analogue scale (VAS). 4 months
Secondary quality of life in IBS-C patients quality of life in IBS-C patients were assessed at pre-and post-intervention using a self-report Irritable Bowel Syndrome-Quality of Life Measure (IBS-QoL). It contains 34 items with 8 sub-classification including dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, sexual, and relationships. The sum of response to this items by every subject were average and transform to 0-100 scale. The higher score indicated better quality of life among IBS-C patients. 4 months
Secondary frequency of defecation and hard stool frequency of defecation and hard stool was evaluated at baseline and end of every month using the visual analogue scale (VAS) 4 months